Proliferation of CD4＋CD25high＋Foxp3＋ regulatory T lymphocytes in ex vivo expanded ascitic fluid from primary and recurrent ovarian carcinoma

다국어 초록 (Multilingual Abstract)

Objective: Regulatory T lymphocytes evoke the immune tolerance by suppressing and inactivating cytotoxic T lymphocytes. The objective of this study was to compare the proportion of regulatory T lymphocytes, precisely defined as CD4＋CD25high＋Foxp3＋ T lymphocytes, in primary and recurrent ovarian carcinoma before and after ex vivo expansion of ascites with interleukin-2 (IL-2).
Methods: Ascitic fluid samples were obtained from 26 patients with ovarian carcinoma. Lymphocytes were isolated from ascites and cell markers were analyzed by flow cytometry using anti-CD3/CD4/CD8/CD16/CD56/CD25 and anti-Foxp3 antibodies. Lymphocytes were incubated for 2 to 3 weeks and expanded ex vivo by IL-2 stimulation and their phenotypes were analyzed by flow cytometry.
Results: Following ex vivo expansion, ascitic fluid lymphocytes increased by a greater extent in the recurrent group than in the primary group. The proportion of ex vivo-expanded lymphocytes changed as follows; CD4＋ T lymphocytes increased, CD8＋ T lymphocytes decreased, and the proportion of CD3−CD16＋56＋ NK cells was unchanged. The proportion of CD4＋CD25high＋Foxp3＋ regulatory T lymphocytes in CD4＋ T lymphocytes increased after ex vivo expansion in both groups, but to a greater degree in the recurrent group.
Conclusion: This study showed that regulatory T lymphocytes, neither cytotoxic T lymphocytes nor NK cells, were extensively increased after ex vivo expansion, especially in recurrent ovarian carcinoma. These results may provide information that helps to guide the future development of adoptive immunotherapy against ovarian carcinoma.

참고문헌 (Reference)

1 Elgert KD, "Tumor-induced immune dysfunction: the macrophage connection" 64 : 275-290, 1998

2 Onizuka S, "Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody" 59 : 3128-3133, 1999

3 Curiel TJ, "Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival" 10 : 942-949, 2004

4 Ochsenbein AF, "Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction" 411 : 1058-1064, 2001

5 Mills KH, "Regulatory T cells: friend or foe in immunity to infection?" 4 : 841-855, 2004

6 O'Garra A, "Regulatory T cells and mechanisms of immune system control" 10 : 801-805, 2004

7 Thompson C, "Regulatory T cells" 4 : 408-414, 2004

8 Liyanage UK, "Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma" 169 : 2756-2761, 2002

9 Mittrucker HW, "Mini-review: regulatory T cells and infection: suppression revisited" 34 : 306-312, 2004

10 Freedman RS, "Large-scale expansion in interleukin-2 of tumor-infiltrating lymphocytes from patients with ovarian carcinoma for adoptive immunotherapy" 167 : 145-160, 1994

11 Wolf AM, "Increase of regulatory T cells in the peripheral blood of cancer patients" 9 : 606-612, 2003

12 Rosenberg SA, "Immunotherapy and gene therapy of cancer" 51 (51): 5074-5079, 1991

13 Bremers AJ, "Immunology and immunotherapy of human cancer: present concepts and clinical developments" 34 : 1-25, 2000

14 Sakaguchi S, "Immunologic tolerance maintained by CD25＋CD4＋ regulatory T cells: their common role in controlling autoimmunity,tumor immunity, and transplantation tolerance" 182 : 18-32, 2001

15 Jonuleit H, "Identification and functional characterization of human CD4＋CD25＋ T cells with regulatory properties isolated from peripheral blood" 193 : 1285-1294, 2001

16 Kono K, "Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell-and natural killer cell-mediated cytotoxicity" 26 : 1308-1313, 1996

17 Read S, "Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25＋CD4＋ regulatory cells that control intestinal inflammation" 192 : 295-302, 2000

18 Woo EY, "Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation" 168 : 4272-7276, 2002

19 Hori S, "Control of regulatory T cell development by the transcription factor Foxp3" 299 : 1057-1061, 2003

20 Gershon RK, "Cell interactions in the induction of tolerance:the role of thymic lymphocytes" 18 : 723-737, 1970

21 Shevach EM, "CD4＋CD25＋ suppressor T cells: more questions than answers" 2 : 389-400, 2002

22 Sasada T, "CD4＋CD25＋ regulatory T cells in patients with gastrointestinal malignancies:possible involvement of regulatory T cells in disease progression" 98 : 1089-1099, 2003

23 Baecher-Allan C, "CD4＋CD25 high regulatory cells in human peripheral blood" 167 : 1245-1253, 2001

24 Kingsley CI, "CD25＋CD4＋ regulatory T cells prevent graft rejection: CTLA-4- and IL-10- dependent immunoregulation of alloresponses" 168 : 1080-1086, 2002

25 Berek JS, "Biologic and immunologic therapies for ovarian cancer" 21 (21): 168-174, 2003

26 Khattri R, "An essential role for Scurfin in CD4＋CD25＋ T regulatory cells" 4 : 337-342, 2003

27 Fontenot JD, "A well adapted regulatory contrivance:regulatory T cell development and the forkhead family transcription factor Foxp3" 6 : 331-337, 2005